Browsing by Author "Chbib, Salma"
Now showing items 1-3 of 3
-
A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data
Rahhal, Alaa; Khir, Fadi; Orabi, Bassant; Chbib, Salma; Al-Khalaila, Osama; Salah Abdelghani, Mohamed; Osman, Omnia; Azzam Ashour, Amr; Al-Awad, Mohammad; Mahfouz, Ahmed; Awaisu, Ahmed; Hussien Aljundi, Amer; Alahmad, Yaser; Alyafei, Sumaya; Rahman Arabi, Abdul... more authors ... less authors ( Elsevier , 2021 , Article)A high-intensity statin is recommended for the secondary prevention of cardiovascular diseases (CVD). However, real-world evidence of the effectiveness of rosuvastatin following acute coronary syndrome (ACS) is scarce. ... -
Cost-effectiveness analysis of dapagliflozin in addition to standard therapy in heart failure with reduced ejection fraction: A Qatari healthcare perspective
Al-Badriyeh, Daoud; Chbib, Salma; Valapila Abdulrouf, Palli; Al Hail, Moza; El Kassem, Wessam; Abushanab, Dina... more authors ... less authors ( Hamad bin Khalifa University Press (HBKU Press) , 2022 , Article)Background: Dapagliflozin has been shown to reduce the risk of heart failure hospitalization and cardiovascular mortality in patients with heart failure with reduced ejection fraction (HFrEF). 1,2 This work aims to determine ... -
Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
Abushanab, Dina; Chbib, Salma; Kaddoura, Rasha; Al Hail, Moza; Abdul Rouf, Palli Valappila; El Kassem, Wessam; Shah, Jassim; Ravindran Nair, Ramesh Kumar; Al-Badriyeh, Daoud... more authors ... less authors ( Taylor & Francis , 2024 , Article)Aim: To evaluate the cost-effectiveness of dapagliflozin added to standard of care (SoC) versus SoC in heart failure with reduced ejection fraction (HFrEF) and without type 2 diabetes mellitus (T2DM) patients from the ...